- Home
- GKOS
GKOS
Glaukos Corporation
as 12-17-2024 4:00pm EST
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 7.4B | IPO Year: | 2015 |
| Target Price: | $143.00 | AVG Volume (30 days): | 496.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $74.75 - $147.65 | Next Earning Date: | 11-04-2024 |
| Revenue: | $360,347,000 | Revenue Growth: | 18.70% |
| Revenue Growth (this year): | 22.68% | Revenue Growth (next year): | 24.98% |
Stock Insider Trading Activity of Glaukos Corporation (GKOS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kliman Gilbert H | GKOS | Director | Dec 11 '24 | Sell | $144.01 | 2,000 | $288,020.00 | 32,336 | |
| Gilliam Joseph E | GKOS | PRESIDENT & COO | Oct 30 '24 | Sell | $138.97 | 2,275 | $316,156.75 | 102,169 |
Latest Glaukos Corporation News
GKOS Breaking Stock News: Dive into GKOS Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
Zacks
6 days ago
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
Zacks
7 days ago
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
Zacks
7 days ago
5 Medical Device Stocks That Survived the 2024 Market Volatility
MT Newswires
7 days ago
Citigroup Upgrades Glaukos to Buy From Neutral, Raises Price Target to $162 From $132
Argus Research
8 days ago
GKOS: What does Argus have to say about GKOS?
TipRanks
11 days ago
Glaukos initiated with a Buy at UBS
MT Newswires
12 days ago
UBS Initiates Glaukos at Buy With $182 Price Target
Compare GKOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GKOS Glaukos Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.